89bio, Inc. (ETNB)

NASDAQ: ETNB · Real-Time Price · USD
8.73
+0.60 (7.38%)
At close: May 2, 2025, 4:00 PM
8.65
-0.08 (-0.92%)
After-hours: May 2, 2025, 4:02 PM EDT
7.38%
Market Cap 1.27B
Revenue (ttm) n/a
Net Income (ttm) -386.67M
Shares Out 145.98M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,526,790
Open 8.49
Previous Close 8.13
Day's Range 8.41 - 8.90
52-Week Range 4.16 - 11.84
Beta 1.47
Analysts Strong Buy
Price Target 27.25 (+212.14%)
Earnings Date May 1, 2025

About ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 11, 2019
Employees 93
Stock Exchange NASDAQ
Ticker Symbol ETNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ETNB stock is "Strong Buy." The 12-month stock price forecast is $27.25, which is an increase of 212.14% from the latest price.

Price Target
$27.25
(212.14% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to tre...

2 days ago - GlobeNewsWire

89bio: A Buy With Strong Market Opportunity In MASH And SHTG

Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better saf...

15 days ago - Seeking Alpha

89bio to Participate in the Leerink Partners Global Healthcare Conference

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

2 months ago - GlobeNewsWire

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ad...

2 months ago - GlobeNewsWire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...

3 months ago - GlobeNewsWire

89bio's Pegozafermin Is Now Gaining Momentum

89bio's Pegozafermin Is Now Gaining Momentum

3 months ago - Seeking Alpha

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...

3 months ago - GlobeNewsWire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...

3 months ago - GlobeNewsWire

89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward

89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 E...

3 months ago - Seeking Alpha

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

New post-hoc analyses reinforce pegozafermin's potential anti-fibrotic effects and the potential utility of non-invasive tests which correlate to histological endpoints New post-hoc analyses reinforce...

6 months ago - GlobeNewsWire

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapi...

6 months ago - GlobeNewsWire

89bio to Participate in the UBS Global Healthcare Conference

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of i...

6 months ago - GlobeNewsWire

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

SAN FRANCISCO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

7 months ago - GlobeNewsWire

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

7 months ago - GlobeNewsWire

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

8 months ago - GlobeNewsWire

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc. has two phase 3 studies underway, known as ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis, which are using pegozafermin to target F2 — F3 and F4 compensated cirrhosis MASH patients respectivel...

9 months ago - Seeking Alpha

89bio Appoints Francis Sarena as Chief Operating Officer

SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

9 months ago - GlobeNewsWire

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

–The Phase 3 ENLIGHTEN-Fibrosis trial in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and the Phase 3 ENLIGHTEN-Cirrhosis trial in patients with compensated cirr...

9 months ago - GlobeNewsWire

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio is a clinical-stage biopharmaceutical company that develops therapies for liver and cardiometabolic conditions. Their drug candidate, pegozafermin, has shown positive results in reducing liver f...

1 year ago - Seeking Alpha

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

-Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session-

1 year ago - GlobeNewsWire

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients with compensated cirrhosis (F4)—

1 year ago - GlobeNewsWire

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

–Initiated Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) metabolic dysfunction-associated steatohepatitis (MASH) patients–

1 year ago - GlobeNewsWire

89bio to Participate in the BofA Securities 2024 Health Care Conference

SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

1 year ago - GlobeNewsWire

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday...

1 year ago - GlobeNewsWire

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

1 year ago - GlobeNewsWire